ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit .



Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
 

Press and Media Inquiries:
Organogenesis
EN
06/06/2024

Underlying

ORGOOrganogenesis Holdings (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment ...

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the Centers for Medicare & Medicaid Services’ (CMS) proposed new payment approach for skin substitutes/cellular and tissue-based ...

4h / 8m 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to n...

May 8, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Supports CMS’ Local Coverage Determination Implementatio...

Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Me...

April 11, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 202...

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time ...

April 7, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Resu...

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. Fourth Quarter 2024 Financial Results Summary: Net revenue of $126.7 million for the fourth quarter of 2024...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch